Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

 Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

Eli Lilly to Initiate P-I Study of LY3819469 for Cardiometabolic Diseases

Shots:

  • Eli Lilly and Dicerna have reported the US FDA’s IND acceptance of LY3819469 to treat cardiometabolic diseases. The IND acceptance triggers $10M as a milestone to Dicerna under the companies’ 2018 research collaboration and licensing agreement
  • LY3819469 is an investigational GalXC RNAi candidate targeting the LPA gene and is the second clinical-stage candidate to emerge from Dicerna’s collaboration with Lilly
  • As per the agreement, Dicerna is eligible to receive ~$350M in development & commercialization milestones for each GalXC hepatocyte target and $355M for each non-hepatocyte target along with royalties on product sales

Click here to­ read full press release/ article | Ref: Businesswire | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post